Objective: We report on the risk of miscarriage with highand low-dosage periconceptional folic acid (FA) supplementation from a double-blind randomized clinical trial for prevention of orofacial cleft recurrence in Brazil. Methods: Women at risk of recurrence of orofacial clefts in their offspring were randomized into high (4 mg/day) and low (0.4 mg/day) doses of FA supplementation. The women received the study pills before pregnancy, and supplementation continued throughout the first trimester. Miscarriage rates were compared between the two FA groups and with the population rate. Results: A total of 268 pregnancies completed the study protocol, with 141 in the 4.0-mg group and 127 in the 0.4-mg group. The miscarriage rate was 14.2 % in the lowdose FA group (0.4 mg/day) and 11.3 % for the high-dose group (4 mg/day) (P = 0.4877). These miscarriage rates are not significantly different from the miscarriage rate in the Brazilian population, estimated to be around 14 % (P = 0.311).
Introduction
Periconceptional use of folic acid (FA) is well known to reduce the occurrence and recurrence risk of neural tube defects (NTDs) [1, 7] . NTDs are common and burdensome congenital malformations that occur during the development of the neural tube until the first 28 days after conception. FA supplementation is recommended worldwide for prevention of NTD occurrence. The World Health Organization (WHO) recommends that women of reproductive age regularly take FA supplements [4] . Some studies have suggested that periconceptional use of FA may also prevent other common congenital anomalies such as occurrence of cleft lip and cleft palate (CL ± P) at low doses and recurrence at higher doses [9] . Cleft lip and cleft palate are widely considered the most common birth defects affecting about 1 infant per 700 live births worldwide with incidence varying by ancestry, socioeconomic status, and demographic region [5] .
In parallel to the evidence on preventive effects, some studies have raised concerns about the safety of FA supplementation including masking vitamin B12 deficiency [8] and increased risk of miscarriage [4] . Although many studies find no increased miscarriage risk, the literature may still be considered mixed on this topic particularly for high FA doses, requiring further investigation [3, 4] . Specifically, there is still limited knowledge about the effects of FA doses ≥ 1.0 mg/day on miscarriage rates as most studies of FA supplementation involved low doses ( < 1.0 mg/day) [4] .
We had been conducting a double-blind randomized clinical trial, the Oral Cleft Prevention Program (OCPP), designed to investigate the effect of high-vs. low-dose FA on preventing the recurrence of cleft lip with or without cleft palate (CL ± P) in a Brazilian population. The treatment involved FA supplementation initiated before pregnancy and continued during the pre-conceptional period until the end of the first trimester of gestation at a dose of 4.0 mg/day compared to a control group taking 0.4 mg/day during the same period. The study participants included women at risk for recurrence of non-syndromic CL ± P (i.e., without other birth defects) who had CL ± P themselves or have had a child with CL ± P. This study provides a unique setting to evaluate the effects of high-dose FA supplementation on miscarriages based on a randomized design. Most previous studies of FA effects on miscarriages were based on non-randomized designs that may suffer from confounding. Therefore, given its double-blinded randomized design, our study provides strengths over most previous studies. In this paper, we report on the miscarriage risks in the high-and low-FA-supplementation groups in the OCPP.
Methods
The OCPP was conducted in six diff erent sites in Brazil in the cities of Bauru, Curitiba, Lajeado, Porto Alegre, Recife, and Salvador, between 2001 and 2010. Each site was part of a center that provides comprehensive care to patients with CL ± P including surgery, speech therapy, dental care, and other needed treatments. These sites were chosen because they are referral centers for patients with CL ± P in Brazil. Subjects were women 16 to 45 years of age who were themselves aff ected with non-syndromic CL ± P or have had a previous child with non-syndromic OFC and who have attended the study centers for their own or their children ' s treatment. Exclusion criteria were as follows: permanent sterilization; history of epilepsy/seizure and use of antiepileptic drugs; syndromic CL ± P; planning to move outside of the study state; consanguineous couples; pregnancy at baseline; and vitamin B12 level < 128.4 pmol/L.
Women were enrolled regardless of whether they were planning on having a child in the future or not. Study subjects were randomized into two groups: low FA dose of 0.4 mg/day and high FA dose of 4.0 mg/day. A low-dose FA supplementation was used as the control group instead of a placebo-control group given the established evidence that low-dose FA reduces NTD occurrence. Aft er screening for eligibility, qualifi ed subjects provided consent and were randomized.
The 0.4-and 4.0-mg study pills were identical in shape and color. The investigators and subjects were blinded to the group assignment. The protocol was approved by the local institutional review board (IRB) of all sites, the National Committee for Ethics in Research in Brazil, and the University of Iowa IRB.
Aft er randomization, subjects were asked to take one FA pill per day beginning at enrollment and continuing until the end of the fi rst trimester of pregnancy. Every 2 months, and until the end of their participation in the study, participants were followed up either in person or by phone to gather information about pregnancy occurrence and health status. Compliance with the intervention was based on counting returned pills or on self-reports of used pills when unused pillboxes were not returned. The sample for the analysis presented here included all women who became pregnant during their participation in the OCPP and who were followed to evaluate the pregnancy outcome. Pregnancy was reported by subjects and was confi rmed by the study as needed using pregnancy tests. Pregnant women were followed bimonthly to inquire about health conditions and pregnancy progress and for pillbox dispensing.
Miscarriage was recorded based on subjects ' self-report of spontaneous abortion at/before 20 weeks of gestation and confi rmed, in most cases, through an interview with the subject ' s healthcare provider. Women who delivered a live-born child were interviewed by the study staff in person with the child. Data were collected at each site using the same questionnaires and study procedures. All data were transmitted regularly to the study ' s Data Coordinating Center (DCC) at the Research Triangle Institute (RTI) International (North Carolina, USA), which maintained the data. The study was also monitored by a Data Safety and Management Board (DSMB) involving experts in perinatology, medicine, and statistics selected by the National Institute of Dental and Craniofacial Research.
We compared miscarriage rates between the two FA groups using a Fisher ' s exact test in order to test the hypothesis that miscarriage rate did not vary between the two FA doses. We also compared the miscarriage rates in each sample to the Brazilian population miscarriage rate of 14 % using a one-sample proportion test. We compared the mean of gestational age at miscarriage between the two FA groups for the subset that had a miscarriage using a t -test. All null hypotheses were tested at a 0.05 level of signifi cance. We used the soft ware SAS 9.2 (SAS Institute, Cary, NC, USA) to perform statistical analyses.
Results
Of 273 pregnancies in the study, 268 completed the study protocol: 141 in the 4.0-mg group and 127 in the 0.4-mg group. There were five lost-to-follow-up pregnancies (1.8 % ) because of address and telephone number changes. Given the randomized design of the study, there were no statistically significant differences between the two FA groups in baseline characteristics that have been associated with miscarriage risk in previous studies such as alcohol consumption, cigarette smoking, maternal age, marital status, education, employment, parity, multivitamin use, and frequency of gynecological visits. Detailed descriptive statistics for these characteristics are reported in Table 1 . Also, use of multivitamins during pregnancy and baseline levels of vitamin B12, serum, and red blood cell folate did not differ between the two groups. Compliance with the study pills was overall comparable between the two FA groups; average compliance was 72.5 (SD = 28.2) in the 0.4-mg group and 79.6 (SD = 34.0) in the 4.0-mg group (P = 0.0681). Table 2 shows the miscarriage rates in the two FA groups. From a total of 268 pregnancies, 34 (12.7 % ) ended in a miscarriage. Occurrence of miscarriage did not differ statistically between the FA groups; miscarriage rate was 14.2 % (18/127) in the 0.4-mg group and 11.3 % (16/141) in the 4.0-mg FA group (P = 0.4877). Also, these miscarriage rates are not significantly different from the miscarriage rate in the Brazilian population, estimated to be around 14 % (P = 0.311) [2] . The mean gestational age at miscarriage was 11.2 (SD = 5.1) weeks for the 0.4-mg group and 8.6 (SD = 3.1) weeks for the 4.0-mg group; the difference was not statistically significant (P = 0.0963). As described in (Table 1 Continued) the literature, we observed that more than three quarters of miscarriages in both study groups occurred at the first trimester of pregnancy. However, occurrence of miscarriage in the first trimester of pregnancy did not differ statistically between groups; first trimester miscarriage rate was 11.0 % (14/127) in the 0.4-mg group and 10.0 % in the 4.0-mg group (P = 0.7851).
Discussion
This study suggests no association between FA supplementation in high or low doses before and during the first trimester of pregnancy and miscarriage risk. The observed miscarriage rates were not significantly different between the two FA groups and from the miscarriage rate of 14 % observed in the Brazilian population [2] . Our study results are consistent with and complement the findings of several previous studies. For instance, Czeizel et al. [3] found no significant difference in miscarriage rates between periconceptional multivitamin supplementation (including 0.8 mg FA) and placebo groups (10.8 % vs. 9.4 % , respectively) in a randomized study of about 5502 pregnancies. Also, there was no statistically significant difference in miscarriage rates in a large study comparing 0.4 mg of FA supplementation vs. no supplementation in China (9.0 % and 9.3 % ) [6] . The OCPP ' s randomized design significantly reduces the chance of confounding due to unobserved characteristics between women in the two FA groups as previously highlighted.
One important study limitation is that the sample is small and only includes women with a history of nonsyndromic CL ± P. This may limit the generalizability of the results to the overall population. Despite the small sample, there was no trend for a higher miscarriage risk with supplementation with a high-dose of FA. Furthermore, there is no evidence that FA may affect miscarriage risk differently in women with cleft history compared to the general population. Therefore, it is reasonable to assume that the results would be applicable to women without cleft history. Furthermore, this question is mostly relevant to women at risk of NTD and CL ± P recurrence, as high-dosage FA supplementation is not justified as a treatment in the general population of women of childbearing age. However, there is a need to replicate the study in a larger sample.
Our study suggests that high-dose FA supplementation at 4 mg/day does not affect miscarriage rates among women with a history of non-syndromic CL ± P. Such high doses have also been suggested for preventing CL ± P recurrence, although there is no evidence yet from a double-blinded randomized design. Our study suggests no concern for elevated miscarriage rates in future studies of the effectiveness of supplementation of 4.0 mg of FA per day in preventing the recurrence of birth defects.
In summary, we found that high dosage of periconceptional FA supplementation (4.0 mg/day) did not increase miscarriage risk compared to low dosage (0.4 mg). Also, miscarriage rates in both groups were not different from the overall population ' s rate. The results suggest that high-dosage FA can be used to prevent the recurrence of NTDs in clinical practice and tested for its effectiveness in preventing CL ± P recurrence without concern about increased miscarriage risks. We acknowledge, however, that FA in both low and high doses may affect other pregnancy ' s outcomes, which require further studies.
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